SynthesisCancer medicine2025
From Gene to Enzyme: Multidimensional Decoding of the GGT Molecular Family and Its Clinical Tumor Diagnosis.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- BCL6B suppresses acute myeloid leukemia progression by transcriptionally repressing GGT5 and modulating MAPK signaling.Biology direct · 2026Article
- Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundGamma-glutamyltransferase (GGT) is a membrane-bound enzyme involved in glutathione metabolism and oxidative stress regulation. Although it is traditionally viewed as a liver function marker, emerging evidence suggests that its aberrant expression is closely associated with tumorigenesis, progression, and therapeutic resistance across multiple solid tumors. However, the comprehensive landscape of the GGT gene family and its clinical value in tumor diagnosis and prognosis remain unclear.
objectiveTo systematically review the multidimensional roles of the GGT molecular family-including gene variants, mRNA isoforms, enzyme activity, and protein isoforms-in tumor biology and clinical oncology and to evaluate their potential as diagnostic and prognostic biomarkers.
methodsWe conducted a comprehensive literature review (PubMed, CNKI; inception-August 2025) focusing on (1) GGT family gene structure, expression patterns, and regulatory mechanisms; (2) GGT mRNA splice variants and isoforms; (3) GGT enzymatic activity and posttranslational modifications; and (4) clinical studies evaluating GGT as a biomarker in solid tumors. Data were synthesized narratively, emphasizing molecular mechanisms and clinical significance.
resultsThe human GGT family comprises 13 homologous genes (e.g., GGT1-7 and GGTLC1-3) localized on chromosomes 20 and 22, which exhibit tissue-specific expression and functional diversity. GGT1 (22q11.23), which is the most extensively studied gene, is highly expressed in renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), gastric cancer (GC), and breast cancer (BRC) and is correlated with poor prognosis and metastasis. GGT5 acts as a tumor suppressor in HCC but promotes progression in gastric cancer via PI3K/AKT pathway activation. GGT7 overexpression predicts poor survival in patients with HCC and glioblastoma. The GGT-II isoform demonstrated 78.7% sensitivity and 92.3% specificity for HCC diagnosis, outperforming AFP (AUC: 0.89 vs. 0.67). Serum GGT activity ≥ 50 U/L independently predicts poor overall survival (OS) in patients with HCC (HR: 1.78, 95% CI: 1.26-2.50). GGT mRNA splice variants (e.g., the GGT-I mRNA-B subtype) enhance early HCC detection when combined with AFP (sensitivity: 98%).
conclusionsThe GGT molecular family plays pleiotropic roles in tumor biology via redox homeostasis, EMT, and immune modulation. The GGT1/5/7 and GGT-II isoforms represent promising biomarkers for early diagnosis, prognosis, and therapeutic targeting in multiple cancers. Future multicenter studies should validate GGT-based biomarker panels and elucidate the mechanisms underlying tissue-specific GGT functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.